Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Country/Region as subject
Language
Journal subject
Affiliation country
Publication year range
1.
Acta Pharmacol Sin ; 44(1): 221-233, 2023 Jan.
Article in English | MEDLINE | ID: mdl-35676531

ABSTRACT

TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [14C]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 µCi) of [14C]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (Tmax) of 0.667 h and a half-life (t1/2) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collected 216 h after administration, accounting for 95.21% of the dose (46.61% in urine and 48.60% in feces). TPN171 underwent extensive metabolism in humans. Twenty-two metabolites were detected in human plasma, urine, and feces using a radioactive detector combined with a high-resolution mass spectrometer. According to radiochromatograms, a glucuronide metabolite of O-dealkylated TPN171 exceeded 10% of the total drug-related components in human plasma. However, according to the Food and Drug Administration (FDA) guidelines, no further tests are needed to evaluate the safety of this metabolite because it is a phase II metabolite, but the compound is still worthy of attention. The main metabolic biotransformation of TPN171 was mono-oxidation (hydroxylation and N-oxidation), dehydrogenation, N-dealkylation, O-dealkylation, amide hydrolysis, glucuronidation, and acetylation. Cytochrome P450 3A4 (CYP3A4) mainly catalyzed the formation of metabolites, and CYP2E1 and CYP2D6 were involved in the oxidative metabolism of TPN171 to a lesser extent. According to the incubation data, M1 was mainly metabolized to M1G by UDP-glucuronosyltransferase 1A9 (UGT1A9), followed by UGT1A7 and UGT1A10.


Subject(s)
Phosphodiesterase 5 Inhibitors , Pulmonary Arterial Hypertension , Humans , Male , Phosphodiesterase 5 Inhibitors/therapeutic use , Pyrimidinones , Biotransformation , Feces , Administration, Oral
2.
Zootaxa ; 4434(1): 49-64, 2018 Jun 14.
Article in English | MEDLINE | ID: mdl-30313199

ABSTRACT

The Oriental species of Allorhynchium van der Vecht, 1963 (Hymenoptera: Vespidae: Eumeninae) are keyed for the first time and their distribution is summarised, with special reference to China and Vietnam. Archancistrocerus Giordani Soika, 1986, is synonymized with Allorhynchium van der Vecht (syn. nov.). Allorhynchium diffinis (Giordani Soika, 1986) is a new combination and A. quadrimaculatum Gusenleitner, 1997, is recorded from Vietnam for the first time.


Subject(s)
Animal Distribution , Wasps , Animals , China , Vietnam
SELECTION OF CITATIONS
SEARCH DETAIL